Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study
Frontiers in Pharmacology · 17.04.2026 · 17
DOI: 10.3389/fphar.2026.1743230 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.04.2026. Verfasst von Stephan Stenglein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, University and University Hospital of Tübingen, Tübingen, Germany. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Introduction
Zapnometinib (ATR-002) is a selective MEK inhibitor designed to modulate the MAPK/ERK pathway, which plays a key role in viral infections and inflammatory diseases. Clinical characterization of its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) is essential to support further development. This Phase I clinical trial was registered under EudraCT number 2021-005225-25.
Methods
This was a Phase I, single-center, randomized, double-blind, placebo-controlled trial conducted in healthy adults. The study included three parts: a single ascending dose (SAD) phase, a multiple ascending dose (MAD) phase, and a drug–drug interaction (DDI) as well as a food-drug interaction (FDI) phase. In the SAD phase, 42 participants received single oral doses of 600, 900, 1,200, or 1,500 mg. In the MAD phase, 29 participants received daily oral doses of 900, 1,200, or 1,500 mg for 7 days. The DDI phase assessed the effect of zapnometinib on CYP2C8 and CYP2C9 activity using repaglinide and celecoxib as probe substrates.
Results
Zapnometinib was well tolerated with no serious adverse events reported. Most treatment-emergent adverse events (TEAEs) were mild to moderate, including gastrointestinal symptoms (e.g., diarrhea, nausea) and headache. PK analysis showed dose-proportional increases in C max and AUC, with a notable food effect that increases bioavailability. PD evaluation demonstrated significant MEK inhibition, evidenced by reduced ERK phosphorylation. Discussion/Conclusion This phase 1 study demonstrates that zapnometinib has a favorable safety and tolerability profile, predictable pharmacokinetics, and potent pharmacodynamic activity. The results support further clinical development of zapnometinib for therapeutic indications involving dysregulated MAPK/ERK signaling.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Immunology, University and University Hospital of Tübingen, Tübingen, Germany.
- Atriva Therapeutics GmbH, Martinsried, Germany.
- Nuvisan GmbH, Neu-Ulm, Germany.
- ACliRA Consulting ApS, Tønder, Denmark.
Förderung
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Stenglein, S., Volk, J., Füll, Y., Reh, C., Haffner, S., Canisius, S., Overend, T., & Planz, O. (2026). Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1743230
Vancouver
Stenglein S, Volk J, Füll Y, Reh C, Haffner S, Canisius S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1743230
BibTeX
@article{Stenglein2026,
author = {Stenglein, Stephan and Volk, Julian and Füll, Yvonne and Reh, Christian and Haffner, Steffen and Canisius, Sebastian and Overend, Tim and Planz, Oliver},
title = {Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1743230}
}
EUVIMED